SCHEMBL24628429

SCHEMBL24628429

Nc1ccccc1N1CCC2(C1)CN(c1ccc(Cl)cc1F)C2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.40
LMNA P02545 2/20 0.40
KDM4E B2RXH2 1/20 0.40
HTT P42858 1/20 0.40
POLB P06746 1/20 0.40
KEAP1 Q14145 1/20 0.39
MAPT P10636 1/20 0.38
MAPK1 P28482 1/20 0.38
GFER P55789 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
DRD4 P21917 1/20 0.38
GRM2 Q14416 1/20 0.38
ADRA2C P18825 1/20 0.37
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
USP2 O75604 1/20 0.35
GAA P10253 1/20 0.35
FFAR4 Q5NUL3 1/20 0.34
SLC6A2 P23975 2/20 0.34
SLC6A3 Q01959 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29772888 1.00 ALDH1A1 (0.40) ALDH1A1LMNAKDM4EHTTPOLB
SCHEMBL24628435 0.96 ALDH1A1 (0.41) ALDH1A1LMNAKDM4EHTTPOLB
SCHEMBL29772891 0.96 ALDH1A1 (0.41) ALDH1A1LMNAKDM4EHTTPOLB
SCHEMBL29932056 0.91 ALDH1A1 (0.42) ALDH1A1LMNAKDM4EHTTPOLB
SCHEMBL23536130 0.91 ALDH1A1 (0.42) ALDH1A1LMNAKDM4EHTTPOLB
SCHEMBL21261239 0.85 POLB (0.54) ALDH1A1LMNAKDM4EHTTPOLB
SCHEMBL24628493 0.81 MAPT (0.51) ALDH1A1LMNAHTTPOLBMAPT
SCHEMBL29772905 0.81 MAPT (0.51) ALDH1A1LMNAHTTPOLBMAPT
SCHEMBL24628136 0.77 MAPT (0.52) ALDH1A1LMNAHTTPOLBMAPT
SCHEMBL29772900 0.77 MAPT (0.52) ALDH1A1LMNAHTTPOLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240299348-A1 MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE CARAWAY THERAPEUTICS, INC. 2024-09-12 US disclosed
WO-2022150461-A1 MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE CARAWAY THERAPEUTICS, INC. (US) 2022-07-14 WO disclosed
WO-2022150461-A1 MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE CARAWAY THERAPEUTICS, INC. (US) 2022-07-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240299348-A1 MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE TRPM5, TRPM6, TRPM2 ALDH1A1 4321/4885LMNA 1155/4885KDM4E 3791/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.